Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?

HER2 dual-equivocal tumours share more similarity with HER2-negative disease in terms of clinico-pathologic features, HER2 mRNA levels, adjuvant systemic treatment patterns and disease outcome, which deserves further clinical evaluation.